By Associate Professor Liz Caldon

Journal articles

Kalyuga M; Gallego-Ortega D; Lee H; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Rosalind launchbury R; Statham A; Armstrong NJ; Alles MC; Adelaide young A; Egger A; Au W; Piggin CL; Evans C; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JMW; Robert i nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ, 2012, 'ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer', PLoS Biology, 10, pp. e1001461, http://dx.doi.org/10.1371/journal.pbio.1001461

Musgrove EA; Caldon CE; Barraclough J; Stone A; Sutherland RL, 2011, 'Cyclin D as a therapeutic target in cancer', Nature Reviews Cancer, 11, pp. 558 - 572, http://dx.doi.org/10.1038/nrc3090

Caldon CE; Sergio CM; Schutte J; Boersma M; Sutherland RL; Carroll J; Musgrove EA, 2009, 'Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc', Molecular and Cellular Biology, 29, pp. 4623 - 4639

Butt A; Caldon CE; Mcneil CM; Swarbrick A; Musgrove EA; Sutherland RL, 2008, 'Cell cycle machinery: Links with genesis and treatment of breast cancer', Advances in Experimental Medicine and Biology, 630, pp. 189 - 205

Musgrove EA; Sergio CM; Loi S; Inman CK; Anderson LR; Alles MC; Pinese M; Caldon CE; Schutte J; Gardiner-Garden M; Ormandy CJ; McArthur G; Butt A; Sutherland RL, 2008, 'Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer', PLoS One, 3, pp. 2987 - 2995

Caldon CE; Swarbrick A; Lee CS; Sutherland RL; Musgrove EA, 2008, 'The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini', Cancer research, 68, pp. 3026 - 3036, http://dx.doi.org/10.1158/0008-5472.CAN-07-3079

Caldon CE; Lee CS; Sutherland RL; Musgrove EA, 2008, 'Wilms` tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation', Oncogene, 27, pp. 126 - 138, http://dx.doi.org/10.1038/sj.onc.1210622

Caldon CE; Daly RJ; Sutherland RL; Musgrove EA, 2006, 'Cell cycle control in breast cancer cells', Journal of Cellular Biochemistry, 97, pp. 261 - 274

Brummer T; Schramek D; Hayes V; Bennett HL; Caldon CE; Musgrove EA; Daly RJ, 2006, 'Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein', The Journal of Biological Chemistry, 281, pp. 626 - 637

Swarbrick A; Akerfeldt M; Lee CS; Sergio CM; Caldon CE; Hunter LJ; Sutherland RL; Musgrove EA; Lee CS, 2005, 'Regulation of cyclin expression and cell cycle progression in breastepithelial cells by the helix-loop-helix protein Id1', Oncogene, 24, pp. 381 - 389

Nadkarni MA; Caldon CE; Chhour KL; Fisher IP; Martin FE; Jacques NA; Hunter N, 2004, 'Carious dentine provides a habitat for a complex array of novel Prevotella-like bacteria', Journal of Clinical Microbiology, 42, pp. 5238 - 5244, http://dx.doi.org/10.1128/JCM.42.11.5238-5244.2004

Kus BM; Caldon CE; Andorn-Broza R; Edwards AM, 2004, 'Functional Interaction of 13 Yeast SCF Complexes with a Set of Yeast E2 Enzymes In Vitro', Proteins: Structure, Function and Genetics, 54, pp. 455 - 467, http://dx.doi.org/10.1002/prot.10620

Paramaesvaran M; Caldon E; Najdi S; Gonzaga G; Hunter N; Nguyen K; McDonald J; Langley DB; Crossley MJ; Collyer CA; Esvaran M, 2003, 'Porphyrin-mediated Cell Surface Heme Capture from Hemoglobin by Porphyromonas gingivalis.', Journal of Bacteriology, 185, pp. 2528 - 2537, http://dx.doi.org/10.1128/JB.185.8.2528-2537.2003

March PE, 2001, 'Evolution of a molecular switch;universal bacterial GTPases regulate ribosome function', Molecular Microbiology, pp. 289 - 297

Conference Papers

O Toole SJ; Swarbrick A; Millar E; McLeod D; Mcneil CM; Qiu MR; Lopez-Knowles E; Caldon E; Oakes SR; Ormandy CJ; Morey AL; Musgrove EA; Henshall SM; Sutherland RL, 2009, 'Aberrent hedgehog signaling is an early event in breast cancer development', in Cancer research, American Association Cancer Research, Philadelphia, PA, pp. 70S - 70S

Kus B; Caldon C; Edwards A, 2003, 'Proteome-wide biochemical screen to identify ubiquitination targets of yeast ubiquitin ligase enzymes', in YEAST, JOHN WILEY & SONS LTD, SWEDEN, GOTHENBURG, pp. S151 - S151, presented at 21st International Conference on Yeast Genetics and Molecular Biology, SWEDEN, GOTHENBURG, 07 July 2003 - 12 July 2003, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000184161800341&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Presentations

Portman N; Milioli HH; Alexandrou S; Coulson R; Young A; Chia KM; Haup S; Haup Y; Caldon L; Lim E, 2019, 'The MDM2 inhibitor NVP-CGM097 synergises with fulvestrant and inhibits Estrogen Receptor positive breast cancer', presented at Hormone-Dependent Cancers (GRS), Newry, USA

Conference Abstracts

Freelander A; laven-Law G; Eshraghi L; Geetha N; Somerville P; Pickering M; Alexandrou S; Caldon CE; Tilley WD; Hickey TE; Lim E, 2023, 'Abstract P4-08-16: Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+AR+ breast cancer models', in Cancer Research, American Association for Cancer Research (AACR), Vol. 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-08-16

Freelander A; Laven-Law G; Eshraghi L; Chia KM; Pickering M; Yong A; Wilkinson A; Alexandrou S; Caldon CE; Hickey TE; Tilley WD; Lim E, 2022, 'Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 82, http://dx.doi.org/10.1158/1538-7445.SABCS21-PD2-02

Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982

Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'Abstract GS2-03: The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 80, pp. gs2-03-gs2-03, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.sabcs19-gs2-03

Aziz D; Lee C; Chin V; Fernandez K; Etemadmoghadam D; Bowtell D; Waring PM; Caldon CE, 2019, 'Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700245&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043

Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001

Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012

Whittle JR; Vaillant F; Policheni AN; Liu K; Pal B; Giner G; Fernandez K; Gray DH; Caldon CE; Smyth GK; Visvader JE; Lindeman GJ, 2018, 'Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-PD7-07

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2017, 'Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 78, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 05 December 2017 - 09 December 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000425489401175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Working Papers

Du Q; Smith G; Luu PL; Ferguson J; Armstrong N; Caldon E; Campbell E; Nair S; Zotenko E; Gould C; Buckley M; Kaczorowski D; Barton K; Deveson I; Smith M; Powell J; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark S, 2020, DNA methylation is required to maintain DNA replication timing precision and 3D genome integrity, http://dx.doi.org10.1101/2020.10.15.338855

Preprints

Phan Z; Ford C; Caldon E, 2023, DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review, http://dx.doi.org/10.1101/2023.05.24.23290442

Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, 2020, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-62718/v1

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized inBRCA1mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, http://dx.doi.org/10.1101/2020.01.29.911883

Du Q; Bert SA; Armstrong NJ; Caldon CE; Song JZ; Nair SS; Gould CM; Luu PL; Khoury A; Qu W; Zotenko E; Stirzaker C; Clark SJ, 2018, Replication timing shapes the cancer epigenome and the nature of chromosomal rearrangements, http://dx.doi.org/10.1101/251280

Back to profile page